PR91401

KAOHSIUNG,Taiwan,Sept.1,2021/PRNewswire=KYODO JBN/--

The first clinical study which has been published in the Journal of Applied

Microbiology documents that SynForU(TM)-HerCare is effective in reducing

vulvovaginal symptoms and recurrences of vaginal candidiasis (VC) in pregnant

women.

SynForU(TM)-HerCare, lactobacilli strains, is designed to improve the quality

of life in pregnant women with VC, one of the most common health issues

affecting women globally. This probiotic blend isolated from dairy, namely

Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus

rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26,

and Lactobacillus delbrueckii subsp. lactis LDL114. Its quality, efficacy and

performance have been tested. It's superior in adhesive ability to Hela cell,

hydrogen peroxide production, and antibacterial activity compared to other

intimate care probiotics in the market.

"Most researches on probiotics and vaginal candidiasis primarily emphasized on

women in general, without specifically targeting pregnant women. While VC may

occur randomly in pregnant women; however, studies indicate that a higher

prevalence was observed in pregnant women regardless of their age, trimester,

parity, occupation and educational levels. When it comes to VC treatment,

studies suggest that probiotics are preferred option compared to antifungal

drugs because these drugs normally come with side effects such as increased

recurrence rate and drug resistance. Thus, we developed further randomized

studies to investigate the potential impact of probiotics on prevention of VC

particularly in pregnant women," says Dr. San Land Young, Human Healthcare

Global Operation Head of SynbioTech.

Seventy-eight subjects at 14-32 weeks of pregnancy with VC, completed the

double-blind, placebo-controlled randomized 8-week study. The intervention

group took lactobacilli probiotics, (two capsules/day of 9.5 log CFU/capsule)

for 8 weeks.

The lactobacilli group shows 45% reduction of vulvovaginal symptoms such as

irritation, discharge and burning (P<0.05), 31% reduction of worry (P=0.001),

34.6% reduction of the impairment of daily activities attributed to VC at

week-8 (P=0.026) whereas the placebo group showed no significant changes in

emotional stress or in social impacts. Notably, the lactobacilli group also

reported 38% decreasing in recurrences of emotional stress at week-8 (P=0.0002

Vs P=0.003) and 33% improvement in social impacts (P=0.006) compared to the

placebo group. In addition, the lactobacilli group also demonstrated higher

defecation times per week (11% increase) (P=0.001) and showed marginally less

constipated (P=0.06) as compared to the placebo group.

The results indicate that supplementation of SynForU(TM)-HerCare reduces

vulvovaginal symptoms, recurrences of VC, and improves emotional and social

distress attributed to VC. Moreover, SynForU(TM)-HerCare showed the potential

benefit in reducing risks of pregnancy-induced constipation. Women can benefit

from compelling effects of SynForU(TM)-HerCare, efficacious and

science-supported probiotics. SynForU(TM)-HerCare is available worldwide now.

Lisa Chen, Marketing Manager of SynbioTech commented, "There are many

probiotics with claims in the market, but science is the key.

SynForU(TM)-HerCare is backed by robust science and it's our commitment to

providing long-term care for women around the globe, thereby making a

difference in their life".

For more information: https://www.synbiotech.com

Reference:

J Appl Microbiol. 2021 May 22. Doi:10.1111/jam.15158.

SOURCE: SYNBIO TECH INC

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=399505

   Caption: SynForU(TM)-HerCare probiotics shows benefits to reduce vaginal yeast infection

in women.